50岁以下男性积极前列腺穿刺策略评估
该研究回顾了Princess Margaret癌症中心2000至2016年间199例50岁以下首次前列腺穿刺患者,采用PSA≥1 ng/ml等积极穿刺策略,发现19%确诊前列腺癌,其中22%为Gleason≥7分,且所有Gleason≥7分患者PSA≥1.5 ng/ml。结论支持对50岁以下PSA≥1.5 ng/ml男性采用积极穿刺策略。
要点
- 50岁以下男性PSA≥1.5 ng/ml时应考虑积极前列腺穿刺。
- PSA<1.5 ng/ml的年轻男性 unlikely 有显著前列腺癌。
- 阳性家族史、PSA上升及前列腺体积小是前列腺癌预测因素。
核心结论
- 对50岁以下PSA≥1.5 ng/ml男性采用积极穿刺策略合理,PSA<1.5 ng/ml者 unlikely 有显著癌。
研究设计与样本
- 回顾性队列研究,查询Princess Margaret癌症中心2000至2016年前列腺穿刺数据库,纳入199例50岁以下因PSA≥1 ng/ml、直肠指检可疑、阳性家族史或经直肠超声可疑病灶行首次穿刺的患者。
主要发现
- 199例中37例(19%)确诊前列腺癌,其中8例(22%)Gleason评分≥7分。
- 确诊前列腺癌者中25例(68%)PSA≥1.5 ng/ml,所有Gleason≥7分患者PSA均≥1.5 ng/ml。
- 19例(51%)前列腺癌超出Epstein主动监测标准。
- 预测前列腺癌的因素包括阳性家族史、PSA上升和较低前列腺体积。
关键数值与推荐
- 穿刺指征包括PSA≥1 ng/ml、直肠指检可疑、阳性家族史或经直肠超声可疑病灶。
- PSA≥1.5 ng/ml与Gleason≥7分前列腺癌相关。
临床怎么用
- 对50岁以下男性,若PSA≥1.5 ng/ml应积极行前列腺穿刺;PSA<1.5 ng/ml者可暂缓穿刺。
- 应特别关注前列腺体积较小和阳性家族史的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Longitudinal cohort studies and guidelines demonstrate that prostate specific antigen 1 ng/ml or greater in younger patients confers an increased risk of delayed prostate cancer death. At our institution we have used an aggressive biopsy strategy in younger patients with prostate specific antigen 1 ng/ml or greater. Our objective was to determine the proportion of detected cancer and specifically clinically significant cancer by this strategy. MATERIALS AND METHODS: The prostate biopsy database at Princess Margaret Cancer Centre was queried for patients younger than 50 years who underwent a first prostate biopsy between 2000 and 2016. We included only patients who underwent prostate biopsy due to prostate specific antigen 1 ng/ml or greater and those with a suspicious digital rectal examination, a positive family history or a suspicious lesion on transrectal ultrasound. All clinical and pathological parameters were analyzed. Patients were stratified according to specific prostate specific antigen values. Multivariable logistic regression was performed to ascertain predictors of any prostate cancer diagnosis and of clinically significant prostate cancer. RESULTS: Of the 199 patients who met study inclusion criteria 37 (19%) were diagnosed with prostate cancer and 8 (22%) had a Gleason score of 7 or greater. Of those diagnosed with prostate cancer 25 (68%) had prostate specific antigen 1.5 ng/ml or greater and all men with a Gleason score of 7 or greater had prostate specific antigen 1.5 ng/ml or greater. Notably 19 patients (51%) had prostate cancer exceeding the Epstein criteria for active surveillance. Factors predicting prostate cancer included a positive family history, rising prostate specific antigen and lower prostate volume. CONCLUSIONS: Our results justify adopting an aggressive prostate biopsy strategy in men younger than 50 years with prostate specific antigen 1.5 ng/ml or greater while patients with prostate specific antigen less than 1.5 ng/ml are unlikely to have significant cancer. Special attention should be given to patients with a smaller prostate and a positive family history.
引用
- Goldberg H, Klaassen Z, Chandrasekar T, et al. Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years. J Urol. 2018. PMID: 29758220. doi:10.1016/j.juro.2018.05.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。